Product Description
Molidustat is a compound which inhibits hypoxia inducible factor prolyl hydroxylase (HIF-PH) activity. HIF-PH inhibitors are being investigated as novel therapies for anemia, especially anemia caused by chronic kindney disease (CKD). It is hoped that HIF-PH inhibitors will provide a more effective alternative to the use of erythropoetin replacement therapy plus iron supplementation in CKD patients. (Sourced from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8456)
Mechanisms of Action: HIF Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Japan
Approved Indications: None
Known Adverse Events: None
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Germany
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Acute Myeloid Leukemia|Myelodysplastic Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MOLIVO-1 | P2 |
Active, not recruiting |
Acute Myeloid Leukemia |
2026-05-08 |
|
| MOLIVO-1/AMLSG33-22 | P2 |
Unknown Status |
Myelodysplastic Syndrome|Acute Myeloid Leukemia |
2026-02-01 |